Volume 4.03 | Jan 26

Mammary Cell News 4.03 January 26, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Inhibiting the HSP90 Chaperone Destabilizes Macrophage Migration Inhibitory Factor and Thereby Inhibits Breast Tumor Progression
Researchers’ findings identify migration inhibitory factor (MIF) as a novel HSP90 client and suggest that HSP90 inhibitors inhibit ErbB2-driven breast tumor growth at least in part by destabilizing MIF. [J Exp Med] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Antiangiogenic Agents Increase Breast Cancer Stem Cells via the Generation of Tumor Hypoxia
Researchers demonstrate that by generating intratumoral hypoxia in human breast cancer xenografts, the antiangiogenic agents sunitinib and bevacizumab increase the population of cancer stem cells. [Proc Natl Acad Sci USA] Abstract

Nuclear Receptors Agonists Exert Opposing Effects on the Inflammation Dependent Survival of Breast Cancer Stem Cells
Researchers’ data reveal that nuclear receptors agonists (6-OH-11-O-hydroxyphenanthrene, retinoic acid, pioglitazone) reduce the inflammation dependent survival of breast cancer stem cells and that peroxisome proliferator-activated receptor α agonist Wy14643 exerts opposite effects on this phenotype. [Cell Death Differ] Abstract

RASSF1A Inhibits Estrogen Receptor α Expression and Estrogen-Independent Signaling: Implications for Breast Cancer Development
Here, researchers show that Ras association domain family 1 isoform A (RASSF1A) inhibits breast cancer growth in vivo, and suppresses estrogen receptor a expression and function. [Oncogene] Abstract

Scavenging of CXCL12 by CXCR7 Promotes Tumor Growth and Metastasis of CXCR4-Positive Breast Cancer Cells
Researchers used dual luciferase imaging to investigate CXCR7-dependent scavenging of CXCL12 in breast tumors in vivo and quantify effects of CXCR7 on tumor growth and metastasis of a separate population of CXCR4+ breast cancer cells. [Oncogene] Abstract

Regulation of IMP3 by Epidermal Growth Factor Receptor Signaling and Repression by Estrogen Receptor ß: Implications for Triple-Negative Breast Cancer
In this study, researchers addressed the hypothesis that signaling pathways, which are characteristic of triple-negative breast carcinomas (TNBCs), impact the expression of insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) and that IMP3 contributes to the function of TNBCs. [Oncogene] Abstract

Tyrosine Phosphorylation of Estradiol Receptor by Src Regulates Its Hormone-Dependent Nuclear Export and Cell Cycle Progression in Breast Cancer Cells
Researchers report that in breast cancer cells, tyrosine phosphorylation of the estradiol receptor α by Src regulates cytoplasmic localization of the receptor and DNA synthesis. [Oncogene] Abstract

Decreased Autocrine EGFR Signaling in Metastatic Breast Cancer Cells Inhibits Tumor Growth in Bone and Mammary Fat Pad
Epidermal growth factor receptor (EGFR) ligand expression was profiled in bone metastatic MDA-MB-231 cells, and agonist-induced signaling was examined in both breast cancer and osteoblast-like cells. [PLoS One] Abstract

Estrogen Receptor-α 36 Mediates Mitogenic Antiestrogen Signaling in ER-Negative Breast Cancer Cells
Here, researchers investigated the molecular mechanisms underlying the antiestrogen signaling in estrogen receptor (ER)-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of endogenous ER-α36. [PLoS One] Abstract

The Cyclin-Like Protein Spy1/RINGO Promotes Mammary Transformation and Is Elevated in Human Breast Cancer
Researchers show for the first time that enhanced levels of Spy1 protein are found in a large number of human breast cancers and that knockdown of Spy1 impairs breast cancer cell proliferation. [BMC Cancer] Abstract

CLINICAL RESEARCH

PI3K/AKT/mTOR Inhibitors in Patients with Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Tumors from patients with breast, cervical, endometrial, and ovarian cancer referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA, KRAS, NRAS, and BRAF mutations. Patients with PIK3CA mutations were treated, whenever feasible, with agents targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. [J Clin Oncol] Abstract

Molecular Alterations between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor
Metastatic breast cancers have historically been presumed to have the same predictive biomarkers as the initial primary tumor. Researchers compared the expression of these biomarkers in a large paired tissue microarray series of primary and subsequent relapsed tumors. [Oncologist] Abstract

ON83_EpiCultVideo_645x110.jpg

INDUSTRY NEWS

Maryland Stem Cell Research Commision Announces New Program for Pre-Clinical Research Grants
The Maryland Stem Cell Research Commission has announced a new program for pre-clinical and clinical research grants. This program will support for-profit companies in advancing medical therapies using human stem cells. [Maryland Stem Cell Research Fund] Press Release

BioReference to Launch Groundbreaking Solid Tumor Genotyping Test through Its GenPath Oncology Laboratory
BioReference Laboratories, Inc. and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital is introducing its groundbreaking solid tumor genotype test. [BioReference Laboratories, Inc.] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW International Workshop on Digital Mammography 2012 – 11th International Workshop on Breast Imaging
July 8-11, 2012
Philadelphia, United States

Visit our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES
Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Fellow (University of Alberta)

Postdoctoral Positions (Cancer Science Institute of Singapore)

Research Postdoctoral Fellow (Institut Curie UMR 144)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us